Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer A provocative signal, but not yet an anticancer effect 1. Retrospective EHR-based study; association does not prove causality. 2. High risk of residual confounding despite propensity score matching. 3. Possible healthy-user effect: GLP-1 RA users may have better follow-up, access, adherence, and metabolic care. 4. Strong calendar-time bias: GLP-1 RA use increased in more recent years, when breast cancer care also improved. 5. Weak exposure definition: ≥2 prescriptions do not prove sustained treatment. 6. No time-varying exposure model; immortal-time bias may persist. 7. Landmark analyses reduce bias but do not replace proper time-varying modeling. 8. The signal weakens against the active comparator SGLT2 inhibitors. 9. Insulin/metformin is a problematic comparator because it may represent a sicker diabetes population. 10. Limited tumor biology: ER/HER2 status, grade, nodal burden, tumor size, Ki-67, and genomic risk are inadequately captured. 11. ER-positive rates appear unrealistically low, suggesting incomplete EHR capture. 12. Cancer treatment data appear incomplete; surgery and radiotherapy rates look clinically implausible. 13. RFS is code-based, not a true clinical recurrence endpoint. 14. No breast cancer–specific survival; all-cause mortality may reflect cardiometabolic benefit rather than anticancer effect. 15. No competing-risk analysis despite substantial non-cancer mortality risk. 16. No weight-loss data; the actual metabolic effect is unknown. 17. Effective follow-up is short despite reporting 10-year estimates. 18. Few patients remain at risk beyond 5 years, weakening 10-year KM estimates. 19. High administrative censoring limits late outcome interpretation. 20. Mechanism remains unclear: anticancer effect, weight loss, metabolic control, or patient selection? jamanetwork.com/journals/jam…

Obesity and overweight are risk factors for several types of cancer. Why? A @JAMA_current review jamanetwork.com/journals/jam…

#Obesity is associated with higher risk for 12 #cancer types and accounts for approximately 10% of annual new cancer cases in the US. 📄 This Review summarizes the primary biological pathways connecting obesity and cancer development. ja.ma/3OPhtgT

@EASOobesityECN Spotlight: Meet @SixtenHarborg, a Physician and Clinical researcher. Sixten works at the intersection of oncology and metabolism, specifically looking at how obesity affects cancer risks and outcomes. Learn more: easo.org/easo-ecn-spotlight-…

Among women with early #BreastCancer postdiagnosis statin initiation was associated with a modest reduction in breast cancer and all-cause mortality. ja.ma/4ocDPW5